Clinical trial · Observational
PRospective Study to Measure the Impact of MammaPrint on Adjuvant Treatment in Hormone Receptor-positive HER2-negative Breast Cancer Patients (PRIMe)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
PRIMe is a prospective, case-only trial designed to measure the impact of MammaPrint on physician chemotherapy intention in the two discordant groups (ET/POOR, CT/GOOD) in stage 1 and 2 HR-positive HER2-negative breast cancer patients. The design also provides for assessment of several important secondary indicators. Eligible patients will have their tumor sample analyzed for MammaPrint, BluePrint and TargetPrint. Patients cannot start treatment before the MammaPrint result is received and taken into consideration for the adjuvant treatment plan.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| BluePrint | Other | — | UNRESOLVED |
| MammaPrint | Other | — | UNRESOLVED |
| TargetPrint | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- ET/GOOD
- description
- Endocrine therapy only.
- interventionNames
- Other: MammaPrint
- Other: BluePrint
- Other: TargetPrint
- label
- CT/POOR
- description
- Chemoendocrine therapy according to national guidelines.
- interventionNames
- Other: MammaPrint
- Other: BluePrint
- Other: TargetPrint
Primary outcomes (2)
- measure
- Measure the impact of MammaPrint on adjuvant treatment decisions in discordant groups (ET/POOR and CT/GOOD) in stage-1/2, HR+, HER2- breast cancer and test whether these impacts each exceed a pre-determined compliance threshold.
- timeFrame
- Up to 6 months after end of treatment.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Women with histologically proven invasive stage 1 and 2 breast cancer * Hormone receptor positive according to local standards * HER2 negative - i.e. IHC 0-1+, or FISH or other ISH non-amplified (locally assessed) * Axillary lymph node status: 0-3 involved (macro metastases i.e. \>2mm OR micro metastases i.e. \>0.2-2mm) * ≥ 18 years of age at time of consent * Patients must be eligible to receive adjuvant chemotherapy and endocrine therapy as defined by a good Karnofsky index, no hematological, cardiological or hepatic contraindications nor any impeding comorbidity * Written informed consent Exclusion Criteria: * ≥4 involved axillary nodes * Multi-centric disease with more than 2 clinically relevant lesions * HR negative OR HER2 positive/amplified (locally assessed) * Previous diagnosis of malignancy unless disease free for 10 years * Metastatic disease * Tumor sample shipped to Agendia with ≤ 30% tumor cells or that fails QA or QC criteria * Women who have started or completed adjuvant chemotherapy or neo-adjuvant chemotherapy for current breast cancer
References
Publications (0)
Data not yet available